HomeCompareSQZ vs EPRT

SQZ vs EPRT: Dividend Comparison 2026

SQZ yields 459.77% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SQZ wins by $32296.76M in total portfolio value
10 years
SQZ
SQZ
● Live price
459.77%
Share price
$0.44
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32296.82M
Annual income
$22,619,113,625.24
Full SQZ calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — SQZ vs EPRT

📍 SQZ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSQZEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SQZ + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SQZ pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SQZ
Annual income on $10K today (after 15% tax)
$39,080.46/yr
After 10yr DRIP, annual income (after tax)
$19,226,246,581.45/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, SQZ beats the other by $19,226,235,666.83/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SQZ + EPRT for your $10,000?

SQZ: 50%EPRT: 50%
100% EPRT50/50100% SQZ
Portfolio after 10yr
$16148.44M
Annual income
$11,309,563,232.98/yr
Blended yield
70.04%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

SQZ
Analyst Ratings
4
Buy
1
Hold
1
Sell
Consensus: Buy
Price Target
$4.00
+819.5% upside vs current
Range: $4.00 — $4.00
Altman Z
-22.9
Piotroski
2/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SQZ buys
0
EPRT buys
0
No recent congressional trades found for SQZ or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSQZEPRT
Forward yield459.77%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$32296.82M$63.4K
Annual income after 10y$22,619,113,625.24$12,840.73
Total dividends collected$31438.26M$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy
Analyst price target$4.00$35.50

Year-by-year: SQZ vs EPRT ($10,000, DRIP)

YearSQZ PortfolioSQZ Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$56,677$45,977.01$11,205$505.18+$45.5KSQZ
2$304,181$243,536.41$12,672$682.46+$291.5KSQZ
3$1,547,006$1,221,532.43$14,490$930.48+$1.53MSQZ
4$7,461,354$5,806,058.08$16,786$1,282.69+$7.44MSQZ
5$34,154,829$26,171,179.52$19,753$1,791.56+$34.14MSQZ
6$148,508,521$111,962,854.47$23,677$2,541.64+$148.48MSQZ
7$613,881,121$454,977,003.60$29,008$3,672.99+$613.85MSQZ
8$2,414,527,788$1,757,674,987.75$36,463$5,425.08+$2414.49MSQZ
9$9,044,589,126$6,461,044,393.43$47,238$8,221.57+$9044.54MSQZ
10$32,296,823,990$22,619,113,625.24$63,385$12,840.73+$32296.76MSQZ

SQZ vs EPRT: Complete Analysis 2026

SQZStock

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with other immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. SQZ Biotechnologies Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.

Full SQZ Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this SQZ vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SQZ vs SCHDSQZ vs JEPISQZ vs OSQZ vs KOSQZ vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.